A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

A decade-long study found that obesity was associated with a significantly increased risk for biologic treatment failure in ...

Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis. | Art Garfunkel is breaking the ...

Sun Pharma announced its partnership with music icon and ILUMYA® (tildrakizumab-asmn) patient, Art Garfunkel, as he shares ...

Researchers from the University of Birmingham (UoB) and the University of Naples Federico II have found that a sequence of ...

The symptoms of psoriasis, a chronic inflammatory condition, can look different on people with differing skin tones. On lighter skin, plaque psoriasis can appear red; on darker skin, it can be ...

Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...

Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...